ClinicalTrials.gg
CompletedNCT06761898Updated Sep 4, 2025

A Study of Different Forms of BGB-43395 and Food Effect in Healthy Participants

A Phase 1 interventional study of BGB-43395 and BGB-43395 in Healthy Volunteers, sponsored by BeiGene. Completed at 1 site in United States. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-09-04.

Sponsored by BeiGene · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Primary completion was May 2025, 1 year 5 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
51
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Study summary

Study to determine the relative bioavailability of BGB-43395 solid dispersion tablet compared to salt tablet in healthy adult participants in Part 1 and the effect of food on the selected BGB-43395 formulation solid dispersion tablet or salt tablet in healthy adult participants in Part 2.

02

Conditions studied

  • Healthy Volunteers

Keywords

  • BGB-43395
  • Relative Bioavailability
  • Effect of Food
  • Pharmacokinetics
03

In context

Lead sponsor

BeiGene is the lead sponsor of 125 studies on the registry; 2 are open to participants now.

Of its 55 completed or terminated interventional studies of FDA-regulated products, 32 (58%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female, of any race, between 18 and 65 years of age
  • between 18.0 and 32.0 kg/m2, inclusive
  • In good health, as determined by no findings from medical history
  • Able to comprehend and are willing to sign the ICF and abide by the study restrictions

Exclusion criteria

Exclusion Criteria:

  • Significant history or clinical manifestation of any metabolic, allergic, dermatological, hepatic, renal, hematological, pulmonary, cardiovascular, gastrointestinal, neurological, respiratory, endocrine, or psychiatric disorder, as determined by the investigator or designee
  • History of significant , intolerance, or allergy to any drug compound, food, or other substance, as determined by the investigator or designee.
  • History of stomach or intestinal surgery or resection that would potentially alter absorption and/or excretion of orally administered drugs (uncomplicated appendectomy and hernia repair are allowed)
  • Confirmed systolic blood pressure >140 or \<90 mmHg, diastolic blood pressure >90 or \<50 mmHg, or pulse rate >100 or \<40 beats per minute. If any parameter is out of range, measurements should be repeated twice. Participants will be excluded if the average of the 3 measurements are outside of the corresponding reference range.
  • History of prolonged /QT interval corrected for heart rate, with QTcF >450 ms for males and >470 ms for females.
  • History or current diagnosis of diabetes, with a ≥6.5% or fasting blood glucose level ≥126 mg/dL at screening (ALT), aspartate aminotransferase (AST), or total >1.5 × (ULN) (except for participants with Gilbert's syndrome, where total bilirubin should not be >2 × ULN) at screening and check-in.
  • \<90 mL/min/1.73 m2 (Chronic Kidney Disease Epidemiology Collaboration (CKD EPI) 2021)
  • \<lower limit of normal (LLN), white blood cell count \<LLN, \<LLN, or count \<LLN at screening and check-in.
  • Positive hepatitis panel and/or positive test.

NOTE: Other protocol defined Inclusion/Exclusion criteria may apply.

Terms in these criteria, in plain language(13)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
51 participants (actual)

Study arms

  • Experimental
    Part 1: Relative Bioavailability

    Participants will receive a single dose of each formulation of BGB-43395 in separate periods across various sequences.

    Drug: BGB-43395

  • Experimental
    Part 2: Food Effect

    Participants will receive three doses of the selected formulation of BGB-43395 under fasted, low-fat, or high-fat conditions in separate periods across various sequences.

    Drug: BGB-43395

Interventions

  • Administered orally as solid dispersion tablet or salt tablet

  • Administered orally as solid dispersion tablet or salt tablet

06

What researchers measure

Primary outcomes

  1. Part 1 and 2: Area Under the Concentration-time Curve from Time 0 Extrapolated to Infinity (AUC0-∞)

    Time frame: PK is assessed on days 1-15 in Part 1 and Days 1- 22 for part 2

  2. Part 1 and 2: Area Under the Concentration-time Curve from Time 0 to the Time of the Last Quantifiable Concentration (AUC0-tlast)

    Time frame: PK is assessed on days 1-15 in Part 1 and Days 1- 22 for part 2

  3. Part 1 and 2: Maximum Observed Concentration (Cmax)

    Time frame: PK is assessed on days 1-15 in Part 1 and Days 1- 22 for part 2

  4. Part 1 and 2: Time of the Maximum Observed Concentration (Tmax)

    Time frame: PK is assessed on days 1-15 in Part 1 and Days 1- 22 for part 2

  5. Part 1 and 2: Apparent Terminal Elimination Half-life (t1/2)

    Time frame: PK is assessed on days 1-15 in Part 1 and Days 1- 22 for part 2

  6. Part 1 and 2: Apparent Total Clearance (CL/F)

    Time frame: PK is assessed on days 1-15 in Part 1 and Days 1- 22 for part 2

  7. Part 1 and 2: Apparent Volume of Distribution (Vz/F)

    Time frame: PK is assessed on days 1-15 in Part 1 and Days 1- 22 for part 2

Secondary outcomes

  1. Number of Participants with Adverse Events (AEs)

    Time frame: Approx 38 days in Part 1 and 45 days in part 2

  2. Number of participants with clinically significant laboratory values

    Time frame: Approx 38 days in Part 1 and 45 days in part 2

  3. Number of participants with clinically significant electrocardiogram (ECG) results

    Time frame: Approx 38 days in Part 1 and 45 days in part 2

  4. Number of participants with clinically significant vital sign measurements

    Time frame: Approx 38 days in Part 1 and 45 days in part 2

07

Study locations

1 site
  • Fortrea Cru, Daytone Beach
    Daytona Beach, Florida 32117-5116, United States
08

References and documents

Individual participant data

Plan to share: Yes

Data sharing details ↗ · www.beigenemedical.com

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jan 2025 to primary completion in May 2025, 4 months.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 31, 2024
First posted
Jan 7, 2025
StartActual
Jan 14, 2025
Primary completionActual
May 20, 2025
CompletionActual
May 20, 2025
Last update
Sep 4, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 4, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06761898
Lead sponsor
BeiGene
Responsible party
Sponsor
First posted
Jan 7, 2025
Start date
Jan 14, 2025
Primary completion
May 20, 2025
Completion
May 20, 2025
Last update
Sep 4, 2025

Study contacts

Study Director Study Director
study director · BeiGene

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: CDK4 Inhibitor BGB-43395

Start the discussion